RAD51 and neoplasm: Rad50, Rad51, Rad54b, Mre11a, Palb2, Brca1 and Bard1 all showed significantly higher expression in resistant tumours compared to responding tumours (Figure 10C–10I, p = 0.05, p < 0.001, p < 0.001, p < 0.001, p = 0.002, p < 0.001 and p = 0.012 respectively).